About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, April 5th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

Saker Aviation Services, Inc. (SKAS)

We are highlighting Saker Aviation Services, Inc. (SKAS) as "One to Watch" for next week here at the QualityStocks Daily Newsletter.

Founded in 2003, Saker Aviation Services, Inc., via their subsidiaries, operates in the Fixed Base Operation (FBO) segment of the general aviation industry in the U.S. The Company provides FBO flight support services through a growing chain of U.S. based facilities. Their dedication is to providing concierge-level aviation services for individuals and corporate clients. The Company's long-term strategy is to build sales through growth within their FBO operations. Saker Aviation Services shares trade on the OTC Markets' OTCQB. The Company has their corporate headquarters in Avoca, Pennsylvania.

Saker's products include, but are not limited to, aircraft fueling, maintenance, repair and overhaul (MRO), hangar/tie-down, facility management, pilot support services, ground handling, operational consulting, as well as other related services for general aviation, commercial, and military aircrafts. In addition, the Company offers private charter service and consulting services for a non-owned FBO facility, as well as operates a heliport FBO.

Mr. Ronald J. Ricciardi is the President & Chief Executive Officer of Saker Aviation Services. Prior to joining the Company, Mr. Ricciardi was President and CEO of P&A Capital Partners, Inc., an entertainment finance company established to fund the distribution of independent films. He was also co-founder, Chairman and CEO of eTurn, Inc., a high technology service provider. Subsequent to a management career at Pepsi-Cola Company and the Perrier Group of America, Mr. Ricciardi was President and CEO of Clearidge, Inc., a leading regional consumer products company.

Saker carries out their operations out at the Downtown Manhattan (New York) Heliport, the Wilkes-Barre/Scranton (Pennsylvania) International Airport, and at the Garden City (Kansas) Regional Airport. Furthermore, they consult to the FBO and operator of the Niagara Falls (New York) International Airport.

This week, Saker Aviation Services announced their financial results for the year ended December 31, 2012. Their revenue grew by 5.2 percent to $16,928,073 for the year ended December 31, 2012. This is in comparison to corresponding year ago period revenue of $16,088,906. Net income for the year was $549,511. This represents an increase of 35.9 percent in comparison to net income of $404,496 in the same period the year prior.

Saker also reported Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization, as adjusted for stock based compensation expense and other income) of $1,664,176 for the year ended December 31, 2012, an improvement of $116,241 or 7.5 percent as compared to Adjusted EBITDA of $1,547,935 in the year ended December 31, 2011. 

We're keeping an eye on Saker Aviation Services, Inc. (SKAS) and tracking them on our radar screens as "One to Watch" next week here at the QualityStocks Daily Newsletter.

We're tracking Saker Aviation Services, Inc. (SKAS) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.

Saker Aviation Services, Inc. (SKAS), closed Friday's trading session at $0.0989, down 0.10%, on 11,700 volume with 3 trades. The average volume for the last 60 days is 14,992 and the stock's 52-week low/high is $0.013/$0.113.

MediSwipe, Inc. (MWIP)

OTCJournal and SmallCapVoice reported this week on MediSwipe, Inc. (MWIP), Stock Analyzer, Elite Traders, First Penny Picks did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in West Palm Beach, Florida, MediSwipe, Inc. is a merchant payment solutions and financial products enterprise for the medicinal marijuana and health care industry. They offer a complete portfolio of secure and reliable transaction processing and security solutions for the medical and healthcare industries. They utilize traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) payment solutions. MediSwipe provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries. These include digital patient records, Electronic Referrals, Credit/Debit Card merchant services, Check Guarantee and elective surgery financing.

The Company additionally offers digitized personal health records in conjunction with Industry Alliance Partners. They offer reliable merchant payment solutions and closed loop pre-paid stored value and loyalty cards as an innovative cash alternative to these regulated and e-commerce businesses specializing within the healthcare sector.

MediSwipe offers services, including merchant account activation, gateway connections, Web development, and social network engines.
They provide online and wireless merchant payment solutions worldwide. Their alliances provide an electronic payment processing family of services enabling merchants to accept various credit and debit cards, as well as ATM cards and ACH check drafts for payment of a retail, service, mail order, or Internet merchant.

Their solutions provide merchants with their own merchant account, online processing of credit cards (Visa, MasterCard, American Express, and Discover), shopping cart links, virtual terminal, and site enablement. Additionally, they have exclusive banking relationships for medical marijuana clients who understand this business and the regulation challenges the Company faces. MediSwipe can shop for the best rate in healthcare credit card processing services to fit their clients' needs.

Today, MediSwipe announced that their proprietary digital patient management and tracking software application developed for the medicinal marijuana sector "MediSwipe DMS", is now available to patients, caregivers, and dispensaries to sign up, and trial at www.MediSwipe.com. The MediSwipe DMS application includes patient registration, digital records management and tracking of all caregiver transactions. These include log-in time, date stamp, quantity, and type of medication. Users under agreement will pay monthly licensing fees for access to the program.

MediSwipe, Inc. (MWIP), closed Friday's trading session at $0.0507, up 14.19%, on 11,498,478 volume with 477 trades. The average volume for the last 60 days is 12,847,490 and the stock's 52-week low/high is $0.001/$0.1274.

Far East Energy Corp. (FEEC)

SmarTrend Newsletters and UltimatePennyStock reported earlier on Far East Energy Corp. (FEEC), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Far East Energy Corp. focuses on coalbed methane (CBM) exploration and development in the People's Republic of China (PRC). Since their establishment, the Company has implemented a strategy to acquire, develop, and exploit growth and to build a geographically focused portfolio of coalbed methane assets with some of the highest per Mcf margins in the industry. Far East Energy's subsidiary is Far East Energy (Bermuda), Ltd.

Through production sharing contracts, Far East Energy has interests in three of the PRC's largest coalbed methane fields. These include the 485,000-acre Shouyang Block in Shanxi Province; the 573,000-acre Qinnan Block in Shanxi Province; and the 265,000-acre Enhong and Laochang areas in Yunnan Province. The Shouyang field is the foundation for growth for Far East Energy. This field is where they are deploying the majority of their technical expertise and capital spending. The Shouyang coals exhibit high permeability and high gas content.

By way of their unique CBM projects in China, the Company can exploit Original Gas in Place (OGIP), estimated to be between 21.3 and 29.2 trillion cubic feet (Tcf). This estimate includes coalbed methane projects granted under the three production sharing contracts (PSCs) in the Shanxi and Yunnan Provinces.

In July 2012, Far East Energy announced the release of an independent engineering report prepared by Resource Investment Strategy Consultants (RISC) regarding the Company's CBM contingent resources located in their Shouyang block in Shanxi Province, as of December 31, 2011. The RISC report estimates the net contingent resources at the 2C (Best Estimate) level of confidence for the Shouyang block under PRMS standards to be approximately 1.1 trillion cubic feet (tcf).

The report estimates net contingent resources at the 3C (High Estimate) level to be approximately 1.3 tcf, and, the 1C (Low Estimate) is 736.1 billion cubic feet.

Last month, the Company announced that their 2013 Shouyang Block drilling campaign is underway. Two drilling rigs are operating on location in the Shouyang Block and additional rigs have been mobilized. The 2013 drilling program is initially targeted at drilling 70 wells in the core 1H Pilot Production Area to speed up the drive toward rising gas production and sales levels; and, an additional 25 appraisal wells across the block, to further identify the most prospective undeveloped sections of the block.

Yesterday, Far East Energy announced that they will host a conference call to update shareholders and other interested parties on Thursday, April 18, 2013 at 9:00 a.m. CDT and 10:00 a.m. EDT. Mr. Michael R. McElwrath, CEO and President, will discuss the current drilling and operations program, and other matters.

Far East Energy Corp. (FEEC), closed Friday at $0.051, up 4.08%, on 4,899,570 volume with 106 trades. The average volume for the last 60 days is 1,029,087 and the stock's 52-week low/high is $0.039/$0.297.

HRT Participações em Petróleo S.A. (HRTPY)

Today we are reporting on HRT Participações em Petróleo S.A. (HRTPY), here at the QualityStocks Daily Newsletter.

HRT Participações em Petróleo S.A. (HRT) is an independent Brazilian oil and natural gas exploration and production (E&P) holding company. Listed on the OTC Pink Current Information, the Company, by way of their subsidiaries, engages in the exploration, development, production, distribution, and sale of oil and natural gas. HRT also engages in the import, export, refining, sale, and distribution of oil, natural gas, fuel, and oil by-products; and the generation, sale, and distribution of electric power. HRT has their headquarters in Rio de Janeiro, Brazil.

Additionally, the Company provides advisory and research services in the environment, oil, natural gas, as well as mining areas. They also provide professional advisory services to companies in these areas, such as collection, chemical analyses, and interpretation of data of a geological, geochemical, and geophysical nature, as well as the remote sensing of such data. Moreover, they provide advisory services in foreign exchange.

The HRT Group's activities focus on oil and natural gas exploration and production. HRT is the operator of exploration blocks in the Solimões Basin (AM) and in Namibia, on the West African Coast. The HRT Group consists of HRT Oil & Gas (HRT O&G) – 55 per cent owner and operator of 21 blocks in the Solimões Basin (AM), besides a 10 percent stake in three blocks in the Recôncavo (BA), Espírito Santo (ES) and Rio do Peixe (PB) basins, and HRT Africa – holder of 12 blocks in offshore Namibia.

HRT holds a selection of 36 exploration onshore and offshore blocks, with an estimate of 7.9 billion BOE (Barrels of Oil Equivalent) among risked prospective and contingent resources. HRT is one of the largest independent Brazilian companies in oil and natural gas E&P in terms of the area of exploration blocks. The Company's portfolio of assets consists of blocks that total 75,425 km² (18.6 million acres) in sedimentary onshore basins in Brazil and offshore in Namibia, with a high potential for oil and natural gas exploration and production.

HRT Participações em Petróleo S.A. (HRTPY), closed today's trading at $1.14, up 1.79%, on 951,209 volume with 393 trades. The average volume for the last 60 days is 523,641 and the stock's 52-week low/high is $0.8609/$3.38.

Rainy River Resources Ltd. (RR.TO)

Today we are highlighting Rainy River Resources Ltd. (RR.TO), here at the QualityStocks Daily Newsletter.

Rainy River Resources Ltd. is a precious metals exploration company whose shares trade on the Toronto Stock Exchange. Their primary asset is the Rainy River Gold Project (100 percent-owned). This Project is a large gold system centered in Richardson Township (part of Chapple Township), in northwestern Ontario, near the Manitoba and U.S. borders. The Rainy River Gold project is an advanced exploration stage project. Rainy River Resources has their headquarters in Toronto, Ontario.

The Rainy River gold project hosts an NI 43-101 compliant gold resource of 1.2 Moz Measured, 5.0 Moz indicated and 2.3 Moz inferred. The Company's August 2012 Preliminary Economic Assessment (PEA) foresees average yearly production of 308,000 of gold and 478,000 ounces of silver over the first 10 years of a combined open pit and underground mining operation. Exploration at the Rainy River Gold Project started as early as 1967. Noranda, International Nickel Corp. of Canada, Hudson's Bay Exploration and Development, and Mingold Resources operated in the area to 1989.

In addition, in 2006, Rainy River Resources acquired a 100 percent interest in certain mineral leases covering 1,725 acres in St. Louis County in northwestern Minnesota. These are referred to as the Mud Creek Property. Based on mineral tenure provisions in Minnesota, subject to performance and payment of rental, these mineral leases expire on September 7, 2055.

This week, Rainy River Resources announced further assay results from the Intrepid Zone at the Rainy River Gold Project in northwestern Ontario. Their Intrepid Zone infill intersected 15.5 g/t gold and 86.6 g/t silver over 9 meters. The Company reports that with the addition of 20 new diamond drill holes released this week, 102 holes have now penetrated the Intrepid Zone over a 410-meter strike length. They have traced the mineralization down-dip for 450 meters. The Intrepid Zone continues to increase in size. Infill drilling demonstrates excellent continuity within the zone.

Rainy River Resources Ltd. (RR.TO), closed Friday's trading session at $2.63, up 5.62%, on 353,969 volume. The stock's 52-week low/high is $2.32/$6.17.

Bio-Matrix Scientific Group, Inc. (BMSN)

Stock Analyzer, PennyStocks24, Investor Ideas, and Paradise Penny Stocks reported recently on Bio-Matrix Scientific Group, Inc. (BMSN), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Bio-Matrix Scientific Group, Inc. (BMSN), via their wholly owned subsidiary, Regen BioPharma, Inc., is a biotechnology company that lists on the OTC Markets' OTCQB. They focus on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies by way of pre-clinical and Phase I/II clinical trials. Bio-Matrix Scientific Group is based in La Mesa, California.

The Company's Regen BioPharma is concentrating on developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advancing intellectual property (IP) licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life.

Regen BioPharma has assessed more than 20,000 stem cell related issued patents, narrowed down to 2,000 patents with commercial applicability. They have further identified 30 patents available for licensing. Regen BioPharma's areas of interest include Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Heart Related illness, as well as Circulatory issues.

Yesterday, Regen BioPharma provided an update on the Company's progress with HemaXellerate and other new developments. Regen BioPharma is currently focusing on two core areas. One is the HemaXellerate Program, based on treating disorders of blood production. The other is their cancer immunotherapy program that leverages specific cells called "dendritic cells" to kill cancer specifically, but not healthy tissue.

Regen BioPharma has developed the HemaXellerate product, which is a patient-specific composition of cells that has previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells. On February 5, 2013, Regen filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to start clinical trials using HemaXellerate for the treatment of patients with aplastic anemia that are resistant to current therapies.

The FDA issued IND # 15376 to Regen BioPharma in response to their IND application. Regen BioPharma has been communicating with the FDA. The FDA informed the Company that, as per FDA procedure, a letter outlining items, which must be addressed prior to initiating clinical trials, would be sent to Regen soon.

Bio-Matrix Scientific Group, Inc. (BMSN), closed Friday's trading session at $0.0041, down 25.45%, on 178,618,757 volume with 749 trades. The average volume for the last 60 days is 85,331,077 and the stock's 52-week low/high is $0.0002/$0.062.

Cloud Star Corp, NV (CLDS)

PennyStocks24, OTCPicks, PennyTrader Publisher, The Best Newsletters, AnotherWinningTrade, Market FN, InvestmentHouse, Stock Research Newsletter, AimHighProfits, Dividend Opportunities, The Trading Report, The Stock Enthusiast, StreetAuthority Daily, and Market Authority reported this week on Cloud Star Corp, NV (CLDS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cloud Star Corp, NV, is a cloud computing company that provides security, technology, and products to the technology marketplace. Listed on the OTC Bulletin Board, they operate in the remote-access computing sector including enhanced security connections. In addition, Cloud Star develops web application security products with their partners. The Company has their corporate headquarters in Newport Beach, California.

The Company offers an all-inclusive solution that includes Cloud Security, Application Security and Mobile Security [BYOD] - {Bring Your Own Device}. Cloud Star has developed patent-protected remote access security devices such as MyComputerKey™.  MyComputerKey™ is the secured means for individuals to access a remote machine (in particular a Cloud based environment from one's desktop computer). MyComputerKey™ is a USB device that inserts into one's home computer to allow them to access a remote Machine or a Cloud based environment.

The Company also has their Cloudstar Enterprise. This evolving set of services includes Network Security, Information Security, as well as Computer Security. In addition, Cloudstar is developing new features to guarding the communication between applications and end-users. Applications are the software within a Cloud based environment that provides different services and functions to the end-users.

Concerning Mobile Security (BYOD), the Company is developing their proprietary Mobile Security product family. They include a Mobile Application that is installed onto the smartphone or tablet.

Last month, Cloud Star announced a Joint Venture and Purchase Option with App Ventures Ltd. of Hong Kong. The agreement provides a technology, development and revenue sharing partnership related to security products for the online applications sector. Furthermore, the Agreement also provides the terms for Cloud Star to acquire App Ventures at any time during the next 12 months. 

This week, Cloud Star announced the hiring of Mr. Wee Kai Ng as Chief Technology Advisor.  Mr. Ng is an application security expert. He will take a vital role in the development of the Company's cloud computing security products in the remote access security division and the new web application security division. Mr. Ng has more than 20 years experience in information technology (IT) working for companies including Apple, Microsoft, Accenture, and Encentuate.

Cloud Star Corp, NV (CLDS), closed Friday's trading session at $1.25, even for the day, on 451,328 volume with 332 trades. The average volume for the last 60 days is 99,204 and the stock's 52-week low/high is $0.11/$1.47.

Titan Pharmaceuticals, Inc. (TTNP)

The Street, SmallCap Network, OTCJournal, and Real Pennies reported earlier on Titan Pharmaceuticals, Inc. (TTNP), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Trading on the OTC Bulletin Board, Titan Pharmaceuticals, Inc. is a biopharmaceutical Company that is developing proprietary therapeutics mainly for the treatment of central nervous system (CNS) disorders. The Company's principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (buprenorphine). Titan Pharmaceuticals has their corporate headquarters in South San Francisco, California.

Probuphine is the first product to utilize ProNeura™ - a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson's disease. The design of Probuphine® is to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. A seven-day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011.

The Probuphine New Drug Application (NDA) underwent submission to the U.S. Food and Drug Administration (FDA) in October of 2012 seeking approval for the treatment of opioid dependence. The Probuphine New Drug Application (NDA) was granted priority review designation with a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2013.  

The goal of Titan Pharmaceuticals is to enter into one or more collaborations with capable pharmaceutical companies to commercialize Probuphine in the United States and global markets, and to develop, potentially, the product for the treatment of chronic pain. In December of 2012, Titan Pharmaceuticals announced an exclusive license agreement with Braeburn Pharmaceuticals to the commercialization rights for Probuphine in the U.S. and Canada.

Titan Pharmaceuticals is also entitled to royalty revenue of 8-10 percent of net sales of Fanapt® (iloperidone). This is an atypical antipsychotic compound undergoing marketing in the U.S. for the treatment of schizophrenia by Novartis Pharma AG under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension).

Last month, Titan announced that the majority of Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) members recognized the favorable benefit-risk profile of Probuphine® and voted for approval (10 positive votes, 4 negative votes and 1 abstention).

Moreover, the committee voted in favor of the effectiveness (10 positive votes to 5 negative votes) and safety (12 positive votes to 2 negative votes, with 1 abstention) of Probuphine. The largest portion of committee members abstained (6 abstentions, 5 positive votes and 4 negative votes) on the vote concerning the Risk Evaluation and Mitigation Strategy (REMS) program, as the program is still in discussion with the FDA.

Titan Pharmaceuticals, Inc. (TTNP), closed today at $1.71, up 2.40%, on 445,538 volume with 241 trades. The average volume for the last 60 days is 908,946 and the stock's 52-week low/high is $0.60/$2.53.

graphic

The QualityStocks
Company Corner

graphic
graphic

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.114, on 3,911,062 volume with 1526 trades. The stock’s average daily volume over the past 60 days is 181,925, and its 52-week low/high is $0.15/$0.295.

Cardium Therapeutics, Inc. reported highlights today for FY12 (ended Dec 31) as well as other key developments, ranging from introduction of the FDA-cleared Excellagen® professional-use wound care product and its ISO 13485:2003 certification (CE Mark expected Q2), to the Generx DNA-based therapeutic for coronary artery disease-related myocardial ischemia. For detailed financial information and other recent highlights, visit Cardium’s news page at http://dtg.fm/1thP.

Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

Cardium Presents Year-End 2012 Financial Results And Recent Developments

Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance

Cardium Receives ISO Certification for Excellagen

VentriPoint Diagnostics Ltd. (VPTDF)

The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.095, up 10.08%, on 15,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 31,050, and its 52-week low/high is $0.073/$0.1721.

VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.

VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.

The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer

VentriPoint Diagnostics Ltd. Company Blog

VentriPoint Diagnostics Ltd. News:

VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease

VentriPoint Announces $2 Million Unit Private Placement

VentriPoint Receives US-FDA Acceptance of 510 (K) Submission for Pulmonary Arterial Hypertension

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.299, up 6.79%, on 169,915 volume with 45 trades. The stock’s average daily volume over the past 60 days is 200,258, and its 52-week low/high is $0.161/$0.55.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update

International Stem Cell Corp. to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update

International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.83, up 1.22%, on 200 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,356, and its 52-week low/high is $0.06/$2.80.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D™ at Society of Toxicology's 52nd Annual Meeting

VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting

VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D™

Cardium Therapeutics, Inc. (CXM) Reports 2012 Financial Results, Recent Developments, and Financing

Today before the opening bell, Cardium made a series of announcements as well as provided a comprehensive update on its ongoing initiatives. An abridged overview is presented below due to the length of the press releases issued. For detailed information, visit Cardium’s news page athttp://dtg.fm/1thP.

Commercialization of FDA-Cleared Excellagen

• Introduced its FDA-cleared Excellagen® professional-use wound care product in March 2012 and entered into a logistics and cold chain services agreement with Smith Medical Partners, a subsidiary of H. D. Smith;

• Awarded ISO 13485:2003 certification for Excellagen, State of California manufacturing license and state clearances to market and sell Excellagen in the U.S., and advanced other international registrations for Excellagen, including CE Mark registration, which is expected in Q2 2013;

• Announced sales and distribution agreements with Academy Medical to market, sell, and distribute Excellagen to its growing base of over 35 U.S. government medical providers, including Veterans Administration and military hospitals;

• Excellagen selected as one of the Top Ten Podiatry Innovations in 2012 by Podiatry Today publication, and awarded the American Podiatric Medical Association’s Seal of Approval for Excellagen’s contributions to improve foot health and mobility;

• Formed the Excellagen Medical Advisory Board comprising leading practitioners, clinicians, and researchers with diversified expertise in the field of advanced wound care, and presented case studies at the Desert Foot 2012 High Risk Diabetic Foot Conference;

• Entered into international agreements with (1) an established pharmaceutical company for the registration, marketing, and distribution of Excellagen in the South Korean market; and (2) Advanced Biosciences Research for the planned commercialization of Excellagen in the Russian Federation and CIS;

• Advanced forward with applications to support the reimbursement process for Excellagen with the Centers for Medicare & Medicaid Services (CMS) and private insurance providers, and broadened marketing and sales efforts into markets with established CPT® codes for surgical debridement procedures and in-hospital surgical markets covered under DRG reimbursement systems.

Advancing Generx Phase 3 Angiogenic Gene Therapy

• Initiated the ASPIRE Phase 3 registration study, a 100-patient randomized and controlled multi-center study being conducted at leading cardiology centers in Russia;

• Published important Generx findings in the peer-reviewed journal Human Gene Therapy Methods demonstrating that Cardium’s innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after a one-time intracoronary administration of adenovector in mammalian hearts;

• Presented at the 2013 Phacilitate Annual Cell & Gene Therapy Forum held in Washington, DC, “Optimizing Phase III Trial Design for Generx (Ad5FGF-4)” on adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and discussed the lessons learned during the past decade of the company’s Generx clinical development program;

• Favorable patent decision in Europe and successful resolution of a long standing competition between Cardium and its licensor, the University of California, and Boston Scientific Corporation and its licensor, Arch Development, over the rights to key methods for the application of cardiovascular gene therapy in the treatment of coronary heart disease, as is employed in the company’s Generx gene therapy candidate.

Health Sciences Business and Other Strategic Product Initiatives

• Acquired To Go Brands® nutraceutical supplement brand platform with over 25 products being developed and sold through established regional and national food, drug, and mass channel retailers at over 10,000 retail locations;

• Announced expansion of the To Go Brands VitaRocks® Kids vitamin products and retail distribution of the newly-designed VitaRocks product line into select Target stores nationwide;

• Reported plans for the partner-enabled clinical development of Genedexa™ (previously referred to as the Excellarate™ product candidate), a DNA-based Phase 2b/3 product candidate initially for the treatment of chronic, non-healing diabetic foot ulcers and representing the first product extension from the company’s FDA-cleared Excellagen technology platform;

• Developed a new in-house partner-enabled product opportunity, LifeAgain™, a medical analytics and e-commerce platform of algorithms and medical-based programs that were developed by Cardium researchers to support a strategically partnered commercialization of specialized survivable risk life insurance underwritings for cancer patients and patients with chronic medical diseases.

Further Announcements

Cardium invested heavily into its current initiatives, spending $2.6 million for research and development and $6.1 million in selling, general, and administrative expenses. The increased expenditure was associated with the market introduction of Excellagen, initiation of the company’s Generx ASPIRE clinical study, and for Cardium’s nutraceutical initiative, which served as the catalyst for the acquisition of To Go Brands.

In other news, Cardium reported a definitive agreement with its largest shareholder for a financing of up to $4.0 million in gross proceeds. The proceeds will be used to further build Cardium’s medical opportunities portfolio, including its FDA-cleared Excellagen product which is being introduced into targeted would care markets, among other things.

Detailed information on Cardium’s commercialization plans for Excellagen and Generx, as well as an overview of the To Go Brands® Nutraceutical Brand Platform and various in-house initiatives, can be found at http://dtg.fm/W5oO.

To learn more about Cardium Therapeutics and its medical portfolio, visit www.CardiumTHX.com

Award Winning Developer Brings Talents to Role as CEO of Soul and Vibe Interactive, Inc. (SOUL)

When video and computer games company Soul and Vibe Interactive announced in February the acquisition of Soul and Vibe Entertainment, the founder and CEO of the entertainment company, Peter Anthony (“Tony”) Chiodo, took over the reins of Soul and Vibe Interactive as CEO and President. The acquisition secured Soul and Vibe Entertainment’s key contractual agreements as assets for Soul and Vibe Interactive, including a license agreement with General Mills, and game development and publishing agreements for the PlayStation 3, PlayStation Vita (PS Vita), Xbox 360, Windows 8, Windows Live, and Windows Phone. But the move also brought to the fore the vital experience of the new CEO and President Tony Chiodo.

Mr. Chiodo is an award-winning director of product development and production, with 22 years in the video and computer games industry. He is responsible for the launch of over 200 video and computer games, and has extensive experience leading software production teams on a worldwide basis, including internal and contracted engineers, artists, and designers. He created and implemented a development process resulting in the release of over 100 frontline and “casual” games during a 4-year period. His achievements include the production and co-design of the critically acclaimed Stoked: Big Air snowboarding series (Xbox 360) and the million-unit selling title, Summer Sports: Paradise Island (Wii).

Products from the internal studio Tony managed resulted in a capital raise of $12 million, which was the second biggest raise in the interactive industry for the year. He has also produced a number of training simulation games for the U.S. Marine Corps as well as DARPA (the Defense Advanced Research Projects Agency). In addition, he has served as a consultant to SiMCare Health and Vital Sims, Minnesota-based software companies that develop simulations for health care providers that help physicians and nurses provide care to patients who suffer from chronic disease. He is also an adjunct faculty member representing the video and computer games industry, teaching “The Business of Video Games” and “The Art, Culture, and Economics of Video Games” at the Institute of Production and Recording in Minneapolis/St. Paul.

For additional information, visit www.SoulAndVibe.com

Seeking Alpha Publishes Article Featuring International Stem Cell Corp. (ISCO)

International Stem Cell Corp. specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

Seeking Alpha yesterday published the following article featuring ISCO:http://seekingalpha.com/article/1320381

The article titled “Curing Parkinson’s: The Alternative Approach – Is There Money To Be Made?” provides an overview of the current treatments available, a few new options under development, and the overall cost of Parkinson’s disease on our economy. ISCO took the spotlight with its parthenogenetic stem cell-based approach, which recently generated positive safety and efficacy data during placebo-controlled studies. For more information on these studies, visit http://dtg.fm/a5Xh.

Ed Liston, author of the article, wrote, “Let me quickly put a few positives for the ISCO treatment… It is a cure of the underlying disease and not mere mitigation of superficially observable symptoms… It uses cells from unfertilized eggs, therefore, there are no ethical issues associated with the cell source… The cells created using the company’s proprietary technique are designed to be compatible with the immune system of the patient and hence, are not likely to be rejected by the patient’s body upon introduction.”

Nearly 1 million Americans are currently affected by Parkinson’s disease, which is caused by the death of dopamine-generating cells in the brain. The total number of new cases of Parkinson’s detected each year in the US is approximately 60,000. According to the Parkinson’s Disease Foundation, the cost of the disease to the US economy is approximately $25 billion a year.

For more information on International Stem Cell Corp. and its hpSC technology, visitwww.InternationalStemCell.com

Accuray, Inc. (ARAY) Reports First Patients Treated with New TomoEDGE Dynamic Jaws Technology

Accuray is a radiation oncology company that develops, manufactures, and sells personalized, innovative treatment solutions. The company’s leading-edge technologies deliver a full range of radiation therapy and radiosurgery treatments, helping patients to live longer, better lives.

The company announced that Heidelberg University Hospital in Germany has treated the world’s first patients with the new TomoEDGE Dynamic Jaws technology combined with VoLO Planning as part of its TomoTherapy System. Heidelberg University Hospital revealed that it successfully treated patients with both prostate and breast cancers.

The TomoEDGE technology permits sharper dose sculpting and reduces treatment time for many patients by roughly half. The result is a precise, yet faster and more customized treatment delivery that is as unique as each patient. The technology also allows those providing the treatment to spare normal tissues while increasing the efficiency of the treatment. The faster treatment time also allows hospitals and clinics to treat more patients per day.

Florian Sterzing, M.D., radiation oncologist with Heidelberg University Hospital, said, “With TomoEDGE we are now able to treat faster the entire spectrum of radiation oncology patients.” For its part, Accuray says it remains committed to providing the most advanced treatments in radiation oncology.

For additional information about Accuray and its technology, visit www.accuray.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Real Pennies
(TRKG)

2.

DrStockPick
(EQLB)

3.

StockHotTips
(CRWE)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251